Metraipolis › archive › dc_0f38342ffc3b

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection — Europe PMC PPR:PPR156949

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR156949
DOI
10.1101/2020.04.29.067983
License (as archived)
CC0-1.0
Archived
2026-11-08T20:27:47.261Z
SHA-256 of the archived text
96f34c498684a349bf117dbc042039b39dbb660cb13816d8d001a7970a377ad8
Stable URL of this page
https://metraipolis.com/documento/dc_0f38342ffc3b

How to cite

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection — Europe PMC PPR:PPR156949 — Europe PMC, https://europepmc.org/article/PPR/PPR156949 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_0f38342ffc3b (Metraipolis archive dc_0f38342ffc3b, sha256 96f34c498684a349bf117dbc042039b39dbb660cb13816d8d001a7970a377ad8)
BibTeX
@misc{dc0f38342ffc3b,
  title = {Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection — Europe PMC PPR:PPR156949},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR156949},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_0f38342ffc3b; sha256 96f34c498684a349bf117dbc042039b39dbb660cb13816d8d001a7970a377ad8},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR156949. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The global pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) has prompted multiple clinical trials to jumpstart search for anti-SARS-CoV-2 therapies from existing drugs, including those with reported in vitro efficacies as well as those ones that are not known to inhibit SARS-CoV-2, such as ritonavir/lopinavir and favilavir. Here we report that after screening 19 antiviral drugs that are either in clinical trials or with proposed activity against SARS-CoV-2, remdesivir was the most effective. Chloroquine only effectively protected virus-induced cytopathic effect at around 30 µM with a therapeutic index of 1.5. Our findings also suggest that velpatasvir, ledipasvir, ritonavir, litonavir, lopinavir, favilavir, sofosbuvir, danoprevir, and pocapavir do not have direct antiviral effect.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: bioRxiv, 2020 (prima pubblicazione 2020-04-29).
Identificativi: DOI 10.1101/2020.04.29.067983.
Pagina: https://europepmc.org/article/PPR/PPR156949 — https://doi.org/10.1101/2020.04.29.067983. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-08T20:24:00.657Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.